Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
$28.06
+2.0%		$25.68
$9.57
▼
$30.99
$1.84B-0.75521,126 shs570,568 shs
CG Oncology, Inc. stock logo
CGON
CG Oncology
$75.10
+0.3%		$67.12
$23.65
▼
$77.00
$6.62B0.23925,978 shs610,786 shs
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
$42.39
+1.4%		$37.39
$10.70
▼
$43.73
$7.24B0.381.89 million shs1.86 million shs
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$100.65
+6.9%		$110.33
$57.79
▼
$130.00
$6.14B0.52701,506 shs850,711 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
0.00%+3.54%-5.46%+24.27%+168.77%
CG Oncology, Inc. stock logo
CGON
CG Oncology
0.00%+5.49%+2.43%+7.87%+196.96%
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
0.00%+8.89%+4.64%+22.02%+286.42%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
0.00%-5.00%-21.18%-6.08%+88.52%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
$28.06
+2.0%		$25.68
$9.57
▼
$30.99
$1.84B-0.75521,126 shs570,568 shs
CG Oncology, Inc. stock logo
CGON
CG Oncology
$75.10
+0.3%		$67.12
$23.65
▼
$77.00
$6.62B0.23925,978 shs610,786 shs
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
$42.39
+1.4%		$37.39
$10.70
▼
$43.73
$7.24B0.381.89 million shs1.86 million shs
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$100.65
+6.9%		$110.33
$57.79
▼
$130.00
$6.14B0.52701,506 shs850,711 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
0.00%+3.54%-5.46%+24.27%+168.77%
CG Oncology, Inc. stock logo
CGON
CG Oncology
0.00%+5.49%+2.43%+7.87%+196.96%
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
0.00%+8.89%+4.64%+22.02%+286.42%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
0.00%-5.00%-21.18%-6.08%+88.52%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
2.73
Moderate Buy$30.277.89% Upside
CG Oncology, Inc. stock logo
CGON
CG Oncology
2.71
Moderate Buy$83.1810.76% Upside
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
2.85
Moderate Buy$45.908.28% Upside
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
2.93
Moderate Buy$137.3336.45% Upside

Current Analyst Ratings Breakdown

Latest BCAX, COGT, MIRM, and CGON Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/7/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$81.00 ➝ $79.00
8/7/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$82.00 ➝ $85.00
8/7/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$82.00 ➝ $85.00
8/6/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D-) ➝ Sell (D)
8/6/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$123.00
8/6/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$137.00
8/6/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$148.00 ➝ $135.00
8/6/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
8/6/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$145.00 ➝ $140.00
8/6/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetMarket Outperform$146.00 ➝ $137.00
8/6/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$185.00 ➝ $140.00
(Data available from 8/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/AN/AN/AN/A$7.33 per shareN/A
CG Oncology, Inc. stock logo
CGON
CG Oncology
$6.23M1,063.58N/AN/A$9.33 per share8.05
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/AN/AN/AN/A$3.84 per shareN/A
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$618.07M9.93$0.05 per share1,974.34($0.17) per share-592.06
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-$137.95M-$2.78N/AN/AN/AN/A-35.89%-33.78%8/11/2026 (Estimated)
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$160.99M-$2.69N/AN/AN/A-3,602.68%-26.58%-25.34%N/A
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-$328.94M-$2.17N/AN/AN/AN/A-104.27%-54.64%8/10/2026 (Estimated)
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-$23.36M-$14.55N/AN/AN/A-139.18%-36.28%-8.54%N/A

Latest BCAX, COGT, MIRM, and CGON Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-$0.8198N/AN/AN/AN/AN/A
8/10/2026Q2 2026
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-$0.5550N/AN/AN/A$0.00 millionN/A
8/6/2026Q2 2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$0.6642-$0.90-$0.2359-$0.90$0.36 million$1.16 million
8/5/2026Q2 2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-$0.7425-$1.06-$0.3175-$1.06$166.33 million$176.24 million
5/11/2026Q1 2026
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-$0.72-$0.93-$0.21-$0.93N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/AN/AN/AN/AN/A
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/AN/AN/AN/AN/A
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/AN/AN/AN/AN/A
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/A
13.85
13.85
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/A
31.30
31.25
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
0.41
15.14
15.14
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
1.28
2.86
1.99

Institutional Ownership

CompanyInstitutional Ownership
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/A
CG Oncology, Inc. stock logo
CGON
CG Oncology
26.56%
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/A
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
13.80%
CG Oncology, Inc. stock logo
CGON
CG Oncology
4.80%
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
6.59%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
8.32%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
3265.70 million56.64 millionN/A
CG Oncology, Inc. stock logo
CGON
CG Oncology
6188.20 million83.97 millionOptionable
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
80170.87 million159.61 millionOptionable
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
14060.98 million55.91 millionOptionable

Recent News About These Companies

Mirum Pharmaceuticals (NASDAQ:MIRM) Upgraded to Hold at Wall Street Zen
August 8 at 2:24 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30947979
Wall Street Zen Upgrades Mirum Pharmaceuticals (NASDAQ:MIRM) to "Hold"
August 8 at 2:23 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/wall-street-zen-upgrades-mirum-pharmaceuticals-nasdaqmirm-to-hold-2026-08-08/
Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Down After Earnings Miss
August 8 at 1:40 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30947492
The Manufacturers Life Insurance Company Grows Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM
August 7 at 4:40 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-the-manufacturers-life-insurance-company-grows-stock-holdings-in-mirum-pharmaceuticals-inc-mirm-2026-08-07/
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
August 7 at 4:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/mirum-pharmaceuticals-inc-nasdaqmirm-receives-consensus-recommendation-of-moderate-buy-from-brokerages-2026-08-07/
Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
August 6 at 7:59 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/mirum-pharmaceuticals-reports-second-quarter-200100823.html
TD Cowen Cuts Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $140.00
August 6 at 3:59 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/td-cowen-cuts-mirum-pharmaceuticals-nasdaqmirm-price-target-to-14000-2026-08-06/
Citizens Says FDA’s 'Unexpected' Phase 3 Request Clouds Mirum’s Near-Term Outlook – MIRM Stock Crashes 15%
August 6 at 2:58 PM  |  msn.comhttps://www.msn.com/en-us/money/other/citizens-says-fda-s-unexpected-phase-3-request-clouds-mirum-s-near-term-outlook-mirm-stock-crashes-15/ar-AA29xrkM
Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised
August 6 at 12:26 PM  |  zacks.comhttps://www.zacks.com/stock/news/2970138/mirum-s-q2-earnings-lag-estimates-revenues-beat-2026-view-raised?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-2970138
Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Down Following Weak Earnings
August 6 at 10:39 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/mirum-pharmaceuticals-nasdaqmirm-shares-gap-down-following-weak-earnings-2026-08-06/
Citizens Jmp Cuts Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $137.00
August 6 at 9:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/citizens-jmp-cuts-mirum-pharmaceuticals-nasdaqmirm-price-target-to-13700-2026-08-06/
HC Wainwright Cuts Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $140.00
August 6 at 8:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-cuts-mirum-pharmaceuticals-nasdaqmirm-price-target-to-14000-2026-08-06/
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Sells $193,733.60 in Stock
August 6 at 6:51 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-mirm-insider-buying-and-selling-2026-08-06/
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call Transcript
August 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4931412-mirum-pharmaceuticals-inc-mirm-q2-2026-earnings-call-transcript
Mirum Pharmaceuticals Q2 Earnings Call Highlights
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/mirum-pharmaceuticals-q2-earnings-call-highlights-2026-08-05/
Mirum Pharmaceuticals (NASDAQ:MIRM) Announces Earnings Results, Misses Estimates By $0.32 EPS
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/mirum-pharmaceuticals-nasdaqmirm-announces-earnings-results-misses-estimates-by-032-eps-2026-08-05/
Compared to Estimates, Mirum Pharmaceuticals (MIRM) Q2 Earnings: A Look at Key Metrics
August 5, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2969188/compared-to-estimates-mirum-pharmaceuticals-mirm-q2-earnings-a-look-at-key-metrics?cid=cs-stocknewsapi-ft-fundamental_analysis|nfm-2969188
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Beats Revenue Estimates
August 5, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2969142/mirum-pharmaceuticals-inc-mirm-reports-q2-loss-beats-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2969142
Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Jolanda Howe Sells 1,840 Shares of Stock
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/mirum-pharmaceuticals-nasdaqmirm-svp-jolanda-howe-sells-1840-shares-of-stock-2026-08-05/
Arrowstreet Capital Limited Partnership Has $6.27 Million Stake in Mirum Pharmaceuticals, Inc. $MIRM
August 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-arrowstreet-capital-limited-partnership-has-627-million-stake-in-mirum-pharmaceuticals-inc-mirm-2026-08-03/
Mirum Pharmaceuticals, Inc. $MIRM Shares Bought by First Trust Advisors LP
July 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-mirum-pharmaceuticals-inc-mirm-shares-bought-by-first-trust-advisors-lp-2026-07-31/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bicara Therapeutics stock logo

Bicara Therapeutics NASDAQ:BCAX

$28.06 +0.55 (+2.00%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$28.35 +0.29 (+1.03%)
As of 08/7/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

CG Oncology stock logo

CG Oncology NASDAQ:CGON

$75.10 +0.25 (+0.33%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$72.20 -2.90 (-3.86%)
As of 08/7/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Cogent Biosciences stock logo

Cogent Biosciences NASDAQ:COGT

$42.39 +0.59 (+1.41%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$42.42 +0.03 (+0.07%)
As of 08/7/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Mirum Pharmaceuticals stock logo

Mirum Pharmaceuticals NASDAQ:MIRM

$100.65 +6.54 (+6.95%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$100.74 +0.09 (+0.09%)
As of 08/7/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas